Pfizer, the top pharmaceutical firm, and the Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM) have developed an AI-driven drug discovery method The novel approach, which was a result of the ground-breaking effort, can potentially escalate the period during which the active substance with the therapeutic potential is identified, the most
